GlassScriptPhysician profile
Leana Oppenheim
NPI 1326487174
$45,064.87
in general payments reported to CMS, 2019-2025
65 companies · $15K in 2025
The $15K reported for 2025 was more than what 91% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,099 · 2020: $216 · 2021: $518 · 2022: $767 · 2023: $12K · 2024: $15K · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $33K · Food and Beverage: $9,070 · Travel and Lodging: $783 · Education: $111.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $32,500.00 |
| Food and Beverage | $9,069.50 |
| Travel and Lodging | $782.58 |
| Education | $111.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $34,663.23 | 2019-2025 | |
| Brainsway USA INC | $692.97 | 2025 | Deep Tms System |
| Ucb, INC. | $652.95 | 2020-2025 | Fintepla, Zilbrysq, Rystiggo |
| Biogen, INC. | $640.62 | 2019-2025 | Vumerity, Tysabri, Skyclarys |
| Pfizer INC. | $523.18 | 2023-2025 | |
| Novartis Pharmaceuticals Corporation | $520.19 | 2019-2025 | |
| Allergan, INC. | $511.58 | 2019-2022 | |
| Ge Healthcare | $435.18 | 2022-2024 | |
| Alexion Pharmaceuticals, INC. | $390.71 | 2019-2025 | Ultomiris, Soliris |
| Neurocrine Biosciences, INC. | $386.06 | 2023-2025 | Ingrezza, Ongentys |
| Takeda Pharmaceuticals U.S.A., INC. | $376.90 | 2022-2025 | Hyqvia |
| Teva Pharmaceuticals USA, INC. | $368.90 | 2019-2025 | Austedo Xr, Austedo Xr |
| Argenx US, INC. | $352.11 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Vanda Pharmaceuticals INC. | $318.47 | 2024-2025 | Ponvory |
| Tanabe Pharma America, INC. | $308.48 | 2024-2025 | Radicava |
Show all 65 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leana Oppenheim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.